SCHEMBL11380

SCHEMBL11380

CCC(F)(c1ccccc1)C(C)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.43
KCNH2 Q12809 2/20 0.43
LMNA P02545 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
KDM4E B2RXH2 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
CYP1A2 P05177 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
KIF11 P52732 3/20 0.41
EPHX1 P07099 4/20 0.40
GRIN2D O15399 2/20 0.38
GRIN1 Q05586 2/20 0.38
GRIN2A Q12879 2/20 0.38
GRIN2B Q13224 2/20 0.38
GRIN2C Q14957 2/20 0.38
OPRM1 P35372 2/20 0.38
CACNA1F O60840 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5291582 0.78 KIF11 (0.49) KIF11
SCHEMBL3364484 0.75 MAPT (0.52) CYP2D6KCNH2LMNACHRM2CHRM1
SCHEMBL13868824 0.74 CYP2D6 (0.50) CYP2D6KCNH2LMNACHRM2CHRM1
SCHEMBL11530 0.74 CYP2D6 (0.40) CYP2D6KCNH2LMNACHRM2CHRM1
SCHEMBL4782888 0.73 CYP2D6 (0.42) CYP2D6KCNH2LMNACHRM2CHRM1
SCHEMBL16314168 0.73 MAPT (0.53) CYP2D6KCNH2LMNACHRM2CHRM1
SCHEMBL28239285 0.73 MAPT (0.53) CYP2D6KCNH2LMNACHRM2CHRM1
SCHEMBL28310656 0.72 MAPT (0.52) CYP2D6KCNH2LMNACHRM2CHRM1
Trifluoromethylbenzene SCHEMBL10587298 0.69 ALDH1A1 (0.56) CYP1A2MAPTKMT2AKIF11EPHX1
SCHEMBL4055704 0.69 CYP2D6 (0.49) CYP2D6KCNH2LMNACHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
EP-2504315-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP CYP2D6 1124/4885KCNH2 4108/4885LMNA 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.